VALANX Biotech and Fina Biosolutions have come together to introduce ClickCRM, a new product that aims to accelerate the development of conjugate vaccines. Conjugate vaccines are known for their enhanced efficacy against bacterial infections compared to polysaccharide vaccines. This improvement is achieved through the conjugation of polysaccharide antigens to protein carriers.
ClickCRM is a ready-to-conjugate version of CRM197, an antigenic carrier protein. It enables the rapid and high-efficiency conjugation of carrier proteins to polysaccharide antigens, which is essential for generating conjugate vaccines. This product has defined conjugation sites that are created using synthetic amino acids compatible with click chemistry, allowing for precise conjugation.
Under the joint IP and licensing agreement, VALANX will produce ClickCRM using its platform technology, incorporating proprietary synthetic amino acids for conjugation. On the other hand, Fina Biosolutions will handle the production, marketing, and commercialization of ClickCRM using their purification and formulation methods for CRM197. ClickCRM is now available for purchase through Fina Biosolutions, along with their other carrier proteins.
This collaboration between VALANX Biotech and Fina Biosolutions showcases the power of platform technology for accurate protein modification. By combining their expertise, they have created a product that will simplify the development of conjugate vaccines, ultimately making them more affordable and accessible. ClickCRM is a welcomed addition to the existing portfolio of carrier proteins offered by Fina Biosolutions.
The CEOs of both companies, Michael Lukesch and Andrew Lees, expressed their excitement about the development of ClickCRM and the impact it will have on vaccine development. They believe that this product will allow researchers to rapidly produce new conjugate vaccine candidates, meeting the quality expectations of regulatory agencies.
Overall, ClickCRM represents a significant advancement in the field of conjugate vaccine development. Its innovative technology and collaborative approach between VALANX Biotech and Fina Biosolutions have the potential to revolutionize the way vaccines are created and bring about positive changes in public health. To learn more about ClickCRM, visit Fina Biosolutions’ website for an overview of carrier proteins.
